CBP-IN-1

β-catenin/CBP-IN-1 is a potent and selective CBP/β-catenin antagonist, extracted from the patent WO2014092154A1. β-catenin/CBP-IN-1 has the potential for the study of liver fibrosis induced by hepatitis virus.

Product information

CAS Number: 1198780-38-9

Molecular Weight: 658.64

Formula: C33H35N6O7P

Chemical Name: β-catenin/CBP-IN-1

Smiles: CN1CC(=O)N2C([C@H](C)N(CC3=CC=CC4=CC=CN=C34)C(=O)[C@@H]2CC2C=CC(=CC=2)OP(O)(O)=O)N1C(=O)NCC1C=CC=CC=1

InChiKey: VHOZWHQPEJGPCC-ISZZHBKVSA-N

InChi: InChI=1S/C33H35N6O7P/c1-22-31-38(29(40)21-36(2)39(31)33(42)35-19-24-8-4-3-5-9-24)28(18-23-13-15-27(16-14-23)46-47(43,44)45)32(41)37(22)20-26-11-6-10-25-12-7-17-34-30(25)26/h3-17,22,28,31H,18-21H2,1-2H3,(H,35,42)(H2,43,44,45)/t22-,28-,31?/m0/s1

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vivo:

β-catenin/CBP-IN-1 (intraperitoneal injection;1mg/kg; 42 days) has a treatment effect on liver fibrosis in hepatic fibrosis Cre/loxP/HCV-MxCreTg mouse model.

References:

1. Takenao Odagami, et al. Prevention or treatment agent for hepatic fibrosis. Patent WO2014092154A1.

Products are for research use only. Not for human use.